CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.19B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.61: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.57%
Annual Rate
CNY 0.20Paid annual
Payout Ratio
83.5%Moderate
Payback Period
64.2 yr
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
7.99BCNY1.19B · vs all stocks (USD)
Trailing P/E
51.04xRevenue (TTM)
1.10BCNY163.73M · vs all stocks (USD)
Profit Margin
10.34%Beta
0.5200xvs all stocks
52-Week Change
-24.43%vs all stocks
Market Capitalization
7.99BCNY1.19B · vs all stocks (USD)
Enterprise Value
4.86BCNY724.96M · vs all stocks (USD)
Trailing P/E
51.04xPrice to Sales (TTM)
6.99xPrice to Book (MRQ)
2.05xEnterprise to Revenue
4.43xEnterprise to EBITDA
31.31xGross Margin
74.43%Profit Margin
10.34%Operating Margin
2.06%Return on Assets (TTM)
0.75%Return on Equity (TTM)
2.97%Revenue (TTM)
1.10BCNY163.73M · vs all stocks (USD)
Revenue per Share (TTM)
1.76CNYUpdated Sep 22, 2026Quarterly Revenue Growth
32.00%Gross Profit (TTM)
848.47MCNY126.65M · vs all stocks (USD)
EBITDA (TTM)
123.82MCNY18.48M · vs all stocks (USD)
Net Income (TTM)
113.41MCNY16.93M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.24%Operating Cash Flow (TTM)
209.10MCNY31.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
13.89MCNY2.07M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.57%vs all stocks
Payout Ratio
83.52%Minority Interest (Equity)
-11.25MCNYFY2025 · Dec 31, 2025Revenue
998.14MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
203.60MCNYFY2025 · Dec 31, 2025Gross Profit
794.55MCNYFY2025 · Dec 31, 2025Operating Income
59.51MCNY8.88M · vs all stocks (USD)
Pre-tax Income
-64.31MCNYFY2025 · Dec 31, 2025Income Tax Expense
-33.77MCNYFY2025 · Dec 31, 2025Net Income
-30.55MCNYFY2025 · Dec 31, 2025EBIT
-54.53MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
211.86MCNYFY2025 · Dec 31, 2025Research & Development
302.71MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
346.56MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
53.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.78MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0405CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0405CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
615.72MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
615.72MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-30.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.59MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-212.93MCNYFY2025 · Dec 31, 2025Free Cash Flow
-317.91MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.38BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-30.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.13MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-41.96MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-145.55MCNYFY2025 · Dec 31, 2025Capital Expenditures
-104.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-450.82MCNYFY2025 · Dec 31, 2025Sale of Investments
687.18MCNYFY2025 · Dec 31, 2025Other Investing Activity
-600.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
130.79MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
493.15MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-385.10MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-199.07MCNYFY2025 · Dec 31, 2025Other Financing Charges
190.97MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
99.95MCNYFY2025 · Dec 31, 2025Shares Outstanding
625.90MSharesUpdated Sep 22, 2026Float Shares
356.73MSharesUpdated Sep 22, 2026% Held by Insiders
50.72%vs all stocks
% Held by Institutions
5.56%vs all stocks
Total Cash (MRQ)
2.78BCNY414.85M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.46CNYUpdated Sep 22, 2026Total Debt (MRQ)
730.19MCNY109.00M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1964xCurrent Ratio (MRQ)
2.43xBook Value per Share (MRQ)
5.98CNYUpdated Sep 22, 2026Total Assets
5.02BCNY749.26M · vs all stocks (USD)
Total Current Assets
3.17BCNYFY2025 · Dec 31, 2025Total Liabilities
1.27BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.85BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
91.66MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.18BCNYFY2025 · Dec 31, 2025Cash
2.38BCNYFY2025 · Dec 31, 2025Cash Equivalents
25.76MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.40BCNYFY2025 · Dec 31, 2025Other Short-term Investments
278.43MCNYFY2025 · Dec 31, 2025Accounts Receivable
92.33MCNYFY2025 · Dec 31, 2025Inventory
263.75MCNYFY2025 · Dec 31, 2025Accounts Payable
146.14MCNYFY2025 · Dec 31, 2025Short-term Debt
603.23MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.42MCNYFY2025 · Dec 31, 2025Common Stock (Book)
423.60MCNYFY2025 · Dec 31, 2025Retained Earnings
729.58MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.75BCNY559.31M · vs all stocks (USD)
Treasury Stock
30.02MCNYFY2025 · Dec 31, 202552-Week Low
9.61CNYUpdated Sep 22, 202652-Week High
17.54CNYUpdated Sep 22, 202652-Week Change
-24.43%vs all stocks
Beta
0.5200xvs all stocks
50-Day MA
11.54CNYUpdated Sep 22, 2026200-Day MA
12.43CNYUpdated Sep 22, 2026Avg 10-Day Volume
7.50MSharesUpdated Sep 22, 2026Avg 30-Day Volume
10.96MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.2400CNYUpdated Sep 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.32Receivables vs revenue divergence: 2.56
Financial Health
Altman Z-Score 4.61: safe zoneNotable
Altman Z-Score: 4.61
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.19B, above the global median of $1.18BNotable
Market cap (USD): 1,193,078,384.953Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sonoscape Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurisco Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Beijing Xiaocheng Technology Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated